A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma

A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)

The purpose of this study is to evaluate the activity of romidepsin in patients with progressive or relapsed peripheral T-cell lymphoma (PTCL) who have already been treated with systemic therapy.

Study Overview

• Status: Completed
• Conditions: Peripheral T-cell Lymphoma
• Intervention / Treatment: Drug: Romidepsin

Detailed Description

This is a Phase II, non-randomized, open-label, single-arm trial. This study is designed on the basis of complete response (CR) or unconfirmed CR [CR(u)] as the measure of efficacy, based on the best overall response of each patient. The sample size of 65 patients evaluable for efficacy would yield lower 95% confidence limits on the rate of CR + CR(u) that would range from 2.2% to 7.7%, if the observed rate of CR + CR(u) ranges from 8% to 15%. The study was amended to include an Extension Phase, during which patients at non-US sites who are benefitting from treatment can continue to receive romidepsin. The Extension Study Phase is active in EU countries where currently no Marketing Authorisation exists for romidepsin. Patients may remain on study until progressive disease occurs or they withdraw their consent and only serious adverse events and study drug administration data will continue to be collected and reported for these patients.

• Study Type: Interventional
• Enrollment (Actual): 131
• Phase: Phase 2

Contacts and Locations

Study Locations

• Australia
  • East Melbourne, Australia, 3002
    • Peter Maccallum Cancer Centre
  • Fitzroy, Australia, 3065
    • St. Vincent Hospital
  • St Leonards, Australia, 2065
    • Royal North Shore Hospital
  • Queensland
    • South Brisbane, Queensland, Australia, 4101
      • Mater Private Medical Centre - Haematology and Oncology Clinics of Australasia Research Centre
• Czechia
  • Brno, Czechia, 625 00
    • University Hospital Brno
  • Hradec Kralove, Czechia, 500 05
    • University hospital Hradec Králové
  • Prague 10, Czechia, 100 34
    • University Hospital of Kralovske Vinohrady
  • Prague 2, Czechia, 128 08
    • Charles University General Hospital
• France
  • Bordeaux, France, 33000
    • Polyclinique Bordeaux Nord Aquitaine
  • Créteil, France, 94010
    • Hôpital Henri Mondor
  • Lille, France, 59037
    • Hopital Claude Huriez
  • Nantes, France, 44093
    • CHU Nantes Hôtel Dieu
  • Paris, France, 75010
    • Hôpital Saint-Louis
  • Pessac, France, 33604
    • Service des Maladies du Sang
  • Pierre Bénite, France, 69495
    • Centre Hospitalier Lyon Sud
  • Rennes, France, 35033
    • Centre Eugene Marquis
  • Rouen Cedex, France, 79038
    • Centre Henri Becquerel
• Germany
  • Berlin, Germany, 13353
    • Charite Universitatsmedizin Berlin campus Virchow Klinikum Centrum fur Tumormedizin
  • Frankfurt a.M., Germany, 60488
    • Krankenhaus Nordwest
  • Göttingen, Germany, 37075
    • Georg-August-Universität Göttingen
  • Köln, Germany, 50937
    • Uniklinik Köln
  • Muenchen, Germany, D-81377
    • Klinikum der Universität München-Großhadern
  • Nürnberg, Germany, D- 90419
    • Klinikum Nürnberg Nord
  • Tuebingen, Germany, 72076
    • UKT Universitaetsklinikum Tuebingen
• Poland
  • Gdansk, Poland, 80-952
    • Klinika Hematologii Akademickie Centrum Kliniczne Akademii Medycznej w Gdansku
  • Kraków, Poland, 31 501
    • Oddzial Kliniczny Kliniki Hematologii
  • Lodz, Poland, 93-510
    • Wojewodzki Szpital Specjalistczny im. Mikolaja Kopernika
  • Warszawa, Poland, 02 781
    • Klinika Nowotworow Ukladu Chlonnego
• Spain
  • Barcelona, Spain, 08035
    • Hospital Universitario Vall d Hebron
  • Madrid, Spain, 28046
    • Hospital Universitario La Paz
  • Madrid, Spain, 28006
    • Hospital de La Princesa
  • Pamplona, Spain, 31008
    • Clinica Universitaria de Navarra
  • Salamanca, Spain, 37003
    • Hospital Universitario de Salamanca
  • Santandar, Spain, 39008
    • Hospital Marques de Valdecilla
• Sweden
  • Lund, Sweden, 22185
    • Lund University Hosptial
  • Uppsala, Sweden, 75185
    • Akademiska Sjukhuset
• Ukraine
  • Dnipropetrovsk, Ukraine, 49102
    • Dnipropetrovsk State Medical Academy
  • Kyiv, Ukraine, 03022
    • National Cancer Institute Department Of Conservative Methods Of Treatment
  • Kyiv, Ukraine, 03115
    • R.E.Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology
  • Lviv, Ukraine, 79044
    • Institute of Blood Pathology and Transfusion Medicine of the AMS of Ukraine
• United Kingdom
  • London, United Kingdom, SE1 9RT
    • Guy's and St. Thomas' Hospital
  • London, United Kingdom, EC1A 7BE
    • Barts Cancer Institute, Queen Mary University of London, Charterhouse Square
  • London, United Kingdom, W12 0HS
    • Catherine Lewis Centre - Hematology Department
  • London Hampstead, United Kingdom, NW3 2QG
    • Royal Free Hospital
  • Southampton, United Kingdom, SO16 6YD
    • Somers Cancer Research Building
• United States
  • California
    • La Jolla, California, United States, 92093
      • Moore UCSD Cancer Center
    • Los Angeles, California, United States, 90095
      • UCLA Division of Hematology Oncology
    • San Francisco, California, United States, 94143-0324
      • University of California, San Francisco
  • Colorado
    • Aurora, Colorado, United States, 80012
      • Rocky Mountain Cancer Centers-Aurora
  • Connecticut
    • New Haven, Connecticut, United States, 06519
      • Yale University
  • District of Columbia
    • Washington, District of Columbia, United States, 20010
      • Washington Hospital Center
    • Washington, District of Columbia, United States, 20007
      • Georgetown University IRB
  • Florida
    • Orlando, Florida, United States, 32806-1124
      • Cancer Centers of Florida, PA
    • Tampa, Florida, United States, 33612-9416
      • H. Lee Moffitt Cancer Center and Research Institute
  • Georgia
    • Atlanta, Georgia, United States, 30322
      • Winship Cancer Institute of Emory University
    • Augusta, Georgia, United States, 30901
      • Augusta Oncology Associates, P.C.
    • Macon, Georgia, United States, 31201
      • Central Georgia Cancer Care
  • Illinois
    • Arlington Heights, Illinois, United States, 60005
      • Cancer Care and Hematology Specialists of Chicagoland
    • Chicago, Illinois, United States, 60612
      • Rush University Medical Center
    • Chicago, Illinois, United States, 60611
      • Hematology Oncology Assoc. of IL Orchard Research LLC
  • Kentucky
    • Louisville, Kentucky, United States, 40207
      • Consultants in Blood Disorders and Cancer
  • Maryland
    • Baltimore, Maryland, United States, 21229-5299
      • St. Agnes - Medical Center
    • Bethesda, Maryland, United States, 20817
      • Center for Cancer and Blood Disorders
    • Bethesda, Maryland, United States, 20892
      • Center for Cancer Research CAMC
  • Massachusetts
    • Boston, Massachusetts, United States, 02111
      • Tufts Medical Center
  • Michigan
    • Detroit, Michigan, United States, 48202
      • Henry Ford Hospital
  • Minnesota
    • Burnsville, Minnesota, United States, 55337
      • Minnesota Oncology Hematology, Pa
  • Missouri
    • Saint Joseph, Missouri, United States, 64507
      • St. Joseph Oncology, Inc
    • Saint Louis, Missouri, United States, 63141
      • Arch Medical Services
  • Nebraska
    • Omaha, Nebraska, United States, 68114
      • Nebraska Cancer Specialists
  • New Jersey
    • Hackensack, New Jersey, United States, 07601
      • Hackensack University Medical Center
  • New York
    • New York, New York, United States, 10021
      • Memorial Sloan-Kettering Cancer Center
    • New York, New York, United States, 10032
      • Columbia University Medical Center
    • New York, New York, United States, 10021
      • Weill Cornell Medical College
  • Ohio
    • Cleveland, Ohio, United States, 44195
      • Taussig Cancer Center Cleveland Clinic Foundation
  • Oregon
    • Portland, Oregon, United States, 97227
      • Northwest Cancer Specialists, P.C.
  • Tennessee
    • Memphis, Tennessee, United States, 38138
      • Accelerated Community Oncology Research Network Inc ACORN
  • Texas
    • Beaumont, Texas, United States, 77702-1449
      • Mamie McFadden Ward Center
    • Dallas, Texas, United States, 75237
      • Methodist Charlton Cancer Center
    • Dallas, Texas, United States, 75390-8565
      • UT Southwestern Medical Center Simmons Comprehensive Cancer Center
    • El Paso, Texas, United States, 79915
      • El Paso Cancer Treatment Center
    • Fort Worth, Texas, United States, 76104
      • Texas Oncology, P.A.-Fort Worth
    • Houston, Texas, United States, 77030-4009
      • UT MD Anderson Cancer Center
    • Midland, Texas, United States, 79701
      • Allison Cancer Center
    • Plano, Texas, United States, 75093
      • US Oncology
    • San Antonio, Texas, United States, 78229
      • University of Texas Health Science Center at San Antonio
    • San Antonio, Texas, United States, 78229
      • HOAST
    • Tyler, Texas, United States, 75702
      • Tyler Cancer Center
    • Waco, Texas, United States, 76712
      • Texas Oncology, PA
  • Washington
    • Seattle, Washington, United States, 98109-1024
      • Fred Hutchinson Cancer Research Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

Patients must fulfill all of the following criteria to be eligible for study participation and have:

• Histologically confirmed PTCL not otherwise specified, angioimmunoblastic T-cell lymphoma, extranodal natural killer (NK)/T-cell lymphoma nasal type, enteropathy- type T-cell lymphoma, subcutaneous panniculitis-like T-cell lymphoma, cutaneous γδ T-cell lymphoma (excludes mycosis fungoides or Sezary syndrome), transformed mycosis fungoides, hepatosplenic T-cell lymphoma, anaplastic large cell lymphoma (ALCL; anaplastic lymphoma kinase [ALK]-1 negative), or patients with ALK 1 expressing ALCL (ALK-1 positive) who have relapsed disease after autologous stem cell transplant (ASCT);
• Age ≥18 years;
• Written informed consent;
• Progressive disease following at least one systemic therapy or refractory to at least one prior systemic therapy;
• Measurable disease according to the International Workshop Response (IWC) criteria and/or measurable cutaneous disease;
• Eastern Cooperative Oncology Group (ECOG) performance status of 0-2;
• Serum potassium ≥3.8 mmol/L and magnesium ≥0.85 mmol/L (electrolyte abnormalities can be corrected with supplementation to meet inclusion criteria);
• Negative urine or serum pregnancy test on females of childbearing potential; and
• All women of childbearing potential must use an effective barrier method of contraception (either an intrauterine contraceptive device [IUCD] or double barrier method using condoms or a diaphragm plus spermicide) during the treatment period and for at least 1 month thereafter. Male patients should use a barrier method of contraception during the treatment period and for at least 1 month thereafter. Hormonal methods of contraception such as the contraceptive pill or patch (particularly those containing ethinyl-estradiol) should be avoided due to a potential drug interaction.

Exclusion Criteria:

Patients are ineligible for entry if any of the following criteria are met:

• Known central nervous system (CNS) lymphoma [computed tomography (CT) or magnetic resonance imaging (MRI) scans are required only if brain metastasis is suspected clinically];
• Chemotherapy or immunotherapy within 4 weeks of study entry (6 weeks if nitrosoureas given);

• Initiation of corticosteroids during study (defined as 7 days prior to Cycle 1 Day 1[C1D1] until study drug discontinuation)

  • Patients treated with a pulse of steroids were to discontinue steroid use 7 days prior to C1D1 and have a repeat CT scan and disease assessment after discontinuation of corticosteroids and before starting romidepsin;
• Concomitant use of any other anti-cancer therapy;
• Concomitant use of any investigational agent;
• Use of any investigational agent within 4 weeks of study entry;

• Any known cardiac abnormalities such as:

  • Congenital long QT syndrome;
  • QTc interval >480 milliseconds (msec);
  • A myocardial infarction within 6 months of C1D1. Patients with a history of myocardial infraction between 6 and 12 months prior to C1D1 who are asymptomatic and have had a negative cardiac risk assessment (treadmill stress test, nuclear medicine stress test, or stress echocardiogram) since the event may participate;
  • Other significant electrocardiogram (ECG) abnormalities including 2nd degree atrio-ventricular (AV) block type II, 3rd degree AV block, or bradycardia (ventricular rate less than 50 beats/min).
  • Symptomatic coronary artery disease (CAD), e.g., angina Canadian Class II-IV. In any patient in whom there is doubt, the patient should be referred to a cardiologist for evaluation;
  • An ECG recorded at screening showing significant ST depression (ST depression of ≥2 mm, measured from isoelectric line to the ST segment at a point 60 msec at the end of the QRS complex). If in any doubt, the patient should have a stress imaging study and, if abnormal, angiography to define whether or not CAD is present;
  • Congestive heart failure (CHF) that meets New York Heart Association (NYHA) Class II to IV definitions and/or ejection fraction <40% by MUGA scan or <50% by echocardiogram and/or MRI;
  • A known history of sustained ventricular tachycardia (VT), ventricular fibrillation (VF), Torsade de Pointes, or cardiac arrest unless currently addressed with an automatic implantable cardioverter defibrillator (AICD);
  • Hypertrophic cardiomyopathy or restrictive cardiomyopathy from prior treatment or other causes (if in doubt, see ejection fraction criteria above);
  • Uncontrolled hypertension, i.e., blood pressure (BP) of ≥160/95; patients who have a history of hypertension controlled by medication must be on a stable dose (for at least one month) and meet all other inclusion criteria;
  • Any cardiac arrhythmia requiring anti-arrhythmic medication;
• Serum potassium <3.8 mmol/L or serum magnesium <0.85 mmol/L (electrolyte abnormalities can be corrected with supplementation to meet inclusion criteria);
• Concomitant use of drugs that may cause a significant prolongation of the QTc;
• Concomitant use of CYP3A4 significant or moderate inhibitors;
• Concomitant use of therapeutic warfarin or another anticoagulant due to a potential drug interaction. Use of a small dose of a anticoagulant to maintain patency of venous access port and cannulas is permitted;
• Clinically significant active infection;
• Known infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C;
• Previous extensive radiotherapy involving ≥30% of bone marrow (e.g., whole pelvis, half spine), excluding patients who have had total body irradiation as part of a conditioning regimen for ASCT;
• Major surgery within 2 weeks of study entry;
• Previous allogeneic stem cell transplant;

• Inadequate bone marrow or other organ function as evidenced by:

  • Hemoglobin <9 g/dL (transfusions and/or erythropoietin are permitted);
  • Absolute neutrophil count (ANC) ≤1.0 × 10^9 cells/L [patients with neutropenia (ANC 1-1.5 10^9 cells/L) as a function of their disease may be supported with granulocyte-colony stimulating factor (G-CSF)];
  • Platelet count <100 × 10^9 cells/L or platelet count <75 × 10^9 cells/L if bone marrow disease involvement is documented;
  • Total bilirubin >2.0 × upper limit of normal (ULN) or >3.0 × ULN in the presence of demonstrable liver metastases;
  • Aspartate transaminase/serum glutamic oxaloacetic transaminase (AST/SGOT) and alanine transaminase/serum glutamic pyruvic transaminase (ALT/SGPT) >2.0 × ULN or >3.0 × ULN in the presence of demonstrable liver metastases; or
  • Serum creatinine >2.0 × ULN;
• Patients who are pregnant or breast-feeding;
• Coexistent second malignancy or history of prior solid organ malignancy within previous 3 years (excluding basal or squamous cell carcinoma of the skin, and in situ carcinoma of the cervix (CIN 1) that has been treated curatively);
• Any prior history of a hematologic malignancy (other than T-cell lymphoma);
• Any significant medical or psychiatric condition that might prevent the patient from complying with all study procedures; or
• Prior exposure to romidepsin (other histone deacetylase inhibitors are allowed).

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Romidepsin; Participants received romidepsin 14 mg/m^2 administered intravenously over 4 hours on Days 1, 8, and 15 of a 28-day cycle. Participants continued on monthly cycles of romidepsin. The planned duration of study therapy was 6 cycles. Patients who responded could continue beyond 6 cycles until disease progression or other withdrawal criteria were met. For participants treated for 12 or more cycles, maintenance dosing (2 doses per cycle) was permitted.

Drug: Romidepsin; Romidepsin intravenously (through a vein) over 4 hours on Days 1, 8 and 15 of each 28-day cycle.; Other Names: Depsipeptide; FK228; ISTODAX

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Participants With a Complete Response According to the International Workshop Response Criteria (IWC) for Non-Hodgkin's Lymphomas (NHL) Assessed by an Independent Review Committee	Complete Response (CR): >75% decrease in size aggregate of nodal index lesions (large and small), complete disappearance of extranodal and non-index lesions; total disappearance of clinical disease including skin involvement; disease-related signs and symptoms, normalization of biochemical abnormalities and reduction in size of spleen or liver so no longer palpable. Unconfirmed CR: all above criteria except all nodal index lesions must have regressed >75% in the sum of the product diameters (SPD) from baseline. Individual nodes previously confluent must have regressed by >75% in their SPD.	Response was assessed after every 2 cycles of treatment and at completion of therapy, up until 30 September 2012 (data cutoff for analysis). Maximum duration on study was 1931 days.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Participants With Objective Disease Response	Objective disease response was defined as patients with a Complete Response, Unconfirmed Complete Response or a Partial Response (PR) according to the IWC 1999 assessed by an independent review committee: CR, Cru defined above, PR defined as ≥50% decrease in size of 6 largest dominant nodes and/or nodal masses & extranodal index lesions and no increase of non-index lesions, liver, or spleen; no new sites of disease evident; skin lesions decreased by ≥50%.	Response was assessed after every 2 cycles of treatment and at completion of therapy, up until 30 September 2012 (data cutoff for analysis). Maximum duration on study was 1931 days.
Duration of Objective Disease Response	Duration of response was defined as the number of days from the date of the first disease response (Complete, Unconfirmed Complete or Partial Response) until the date of progression and was determined using Kaplan-Meier product-limit estimates. Progression was defined as: a ≥50% increase from the nadir in the individual sum of the products of the diameters of any index lesion; the reappearance of pathology, enlargement of liver/spleen, or unequivocal progression of non-measurable disease or appearance of any new lesions.	Response was assessed after every 2 cycles of treatment and at completion of therapy, up until 30 September 2012 (data cutoff for analysis). Maximum duration on study was 1931 days.
Duration of Complete Disease Response	Duration of response was defined as the number of days from the date of the first disease response (Complete or Unconfirmed Complete) until the date of progression and was determined using Kaplan-Meier product-limit estimates. Progression was defined as: a ≥50% increase from the nadir in the individual sum of the products of the diameters of any index lesion; the reappearance of pathology, enlargement of liver/spleen, or unequivocal progression of non-measurable disease or appearance of any new lesions.	Response was assessed after every 2 cycles of treatment and at completion of therapy, up until 30 September 2012 (data cutoff for analysis). Maximum duration on study was 1931 days.
Time to Disease Progression	Time to progression (≥50% increase from the nadir in the individual sum of the products of the diameters of any index lesion; the reappearance of pathology, enlargement of liver/spleen, or unequivocal progression of non-measurable disease or appearance of any new lesions) was defined as the duration from the date of the first study drug dose to the date of relapse or progression as reported by the independent review committee and was determined using Kaplan-Meier product-limit estimates.	Response was assessed after every 2 cycles of treatment and at completion of therapy, up until 30 September 2012 (data cutoff for analysis). Maximum duration on study was 1931 days.
Change in Eastern Cooperative Oncology Group (ECOG) Performance Status	The ECOG scale is as follows: Grade 0: Fully active, able to perform all pre-disease activities without restriction; Grade 1: Restricted in physically strenuous activity, ambulatory, able to carry out light work; Grade 2: Ambulatory and capable of all self-care but unable to work. Up and about more than 50% of waking hours; Grade 3: Capable of only limited self-care, confined to bed or chair > 50% of waking hours; Grade 4: Completely disabled. Cannot carry on any self-care. Confined to bed or chair. Data reported is the shift from Baseline ECOG score to best on-study assessment score.	From Baseline up until 30 September 2012 (data cutoff for analysis). Maximum duration on study was 1931 days.
Number of Participants With Treatment Emergent Adverse Events (TEAEs)	An adverse event or experience (AE) is defined as any untoward medical occurrence, which does not necessarily have to have a causal relationship with this treatment. A serious AE is any untoward medical occurrence that at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is an important medical event or condition. Related AEs are defined as those considered by the Investigator to have a possible, probable, or very likely/certain relationship to the study drug. AEs were graded as mild (1), moderate (2), severe (3), lifethreatening (4), or death (5). TEAEs occurred from the first dose of study medication through the end of the study (30 days post last dose) or any event that was present at baseline but worsened in intensity or was subsequently considered drug-related by the Investigator through end of study.	From first dose of study treatment until the final study visit, which occurred 30 days after receiving the last dose. Mean duration of treatment up until 30 September 2012 (data cutoff for analysis) was 169 days.

Collaborators and Investigators

• Sponsor: Celgene
• Investigators: Study Director: Myron Czuczman, MD, Celgene

Publications and helpful links

General Publications

• Foss F, Pro B, Miles Prince H, Sokol L, Caballero D, Horwitz S, Coiffier B. Responses to romidepsin by line of therapy in patients with relapsed or refractory peripheral T-cell lymphoma. Cancer Med. 2017 Jan;6(1):36-44. doi: 10.1002/cam4.939. Epub 2016 Dec 16.
• Shustov A, Coiffier B, Horwitz S, Sokol L, Pro B, Wolfson J, Balser B, Eisch R, Popplewell L, Prince HM, Allen SL, Piekarz R, Bates S. Romidepsin is effective and well tolerated in older patients with peripheral T-cell lymphoma: analysis of two phase II trials. Leuk Lymphoma. 2017 Oct;58(10):2335-2341. doi: 10.1080/10428194.2017.1295143. Epub 2017 Mar 7.
• Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, Caballero D, Borchmann P, Morschhauser F, Wilhelm M, Pinter-Brown L, Padmanabhan S, Shustov A, Nichols J, Carroll S, Balser J, Balser B, Horwitz S. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol. 2012 Feb 20;30(6):631-6. doi: 10.1200/JCO.2011.37.4223. Epub 2012 Jan 23.
• Horwitz S, Coiffier B, Foss F, Prince HM, Sokol L, Greenwood M, Caballero D, Morschhauser F, Pinter-Brown L, Iyer SP, Shustov A, Nichols J, Balser J, Balser B, Pro B. Utility of (1)(8)fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma. Ann Oncol. 2015 Apr;26(4):774-779. doi: 10.1093/annonc/mdv010. Epub 2015 Jan 20.
• Foss F, Horwitz S, Pro B, Prince HM, Sokol L, Balser B, Wolfson J, Coiffier B. Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial. J Hematol Oncol. 2016 Mar 10;9:22. doi: 10.1186/s13045-016-0243-8. Erratum In: J Hematol Oncol. 2017 Sep 18;10 (1):154.
• Foss F, Coiffier B, Horwitz S, Pro B, Prince HM, Sokol L, Greenwood M, Lerner A, Caballero D, Baran E, Kim E, Nichols J, Balser B, Wolfson J, Whittaker S. Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma. Biomark Res. 2014 Sep 8;2:16. doi: 10.1186/2050-7771-2-16. eCollection 2014.
• Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, Caballero D, Morschhauser F, Wilhelm M, Pinter-Brown L, Padmanabhan Iyer S, Shustov A, Nielsen T, Nichols J, Wolfson J, Balser B, Horwitz S. Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses. J Hematol Oncol. 2014 Jan 23;7:11. doi: 10.1186/1756-8722-7-11.

Study record dates

Study Major Dates

• Study Start (Actual): June 19, 2007
• Primary Completion (Actual): November 11, 2010
• Study Completion (Actual): May 17, 2018

Study Registration Dates

• First Submitted: January 23, 2007
• First Submitted That Met QC Criteria: January 23, 2007
• First Posted (Estimate): January 25, 2007

Study Record Updates

• Last Update Posted (Actual): February 11, 2020
• Last Update Submitted That Met QC Criteria: January 29, 2020
• Last Verified: January 1, 2020

More Information

Terms related to this study

• Keywords: T-cell lymphoma; peripheral T-cell lymphoma; romidepsin
• Additional Relevant MeSH Terms: Immune System Diseases; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Lymphoma, Non-Hodgkin; Lymphoma; Lymphoma, T-Cell; Lymphoma, T-Cell, Peripheral; Antineoplastic Agents; Antibiotics, Antineoplastic; Romidepsin
• Other Study ID Numbers: GPI-06-0002; 2006-006228-21 (EudraCT Number)